Loading...
By the Editors
In a biological first, researchers report that they have used the gene editing tool CRISPR to repair the genetic mutation MYBPC3 — which causes hypertrophic cardiomyopathy — in human embryos.
However, writing in Nature, they caution that "much remains to be considered before clinical applications, including the reproducibility of the technique with other heterozygous mutations."
Comment
LINK(S):
Nature article (Free)
New York Times story (Free)
Background: NEJM Journal Watch General Medicine coverage of CRISPR (Your NEJM Journal Watch registration required)